Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEACH trial of pomalidomide for immune enhancement in HIV
2024-512797-10-00Phase 2Authorised
- Sponsor
- Central Denmark Region
- Start
- Feb 2025
- Modality
- Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial in human immunodeficiency virus infection (HIV) comparing Pomalidomide with Placebo (2 arms). Primary endpoints: Primary safety endpoint and Primary efficacy endpoint. Planned start Feb 2025; status: authorised.
02
Drugs
pomalidomide
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2024-512797-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512797-10-00.